July 26, 2022
The year 2021 was an eventful one for Biogen and our portfolio, and one of continued execution across our base business. Neuroscience, Biogen’s principal area of focus, is an attractive field with great potential for innovation and scientific breakthroughs that address significant unmet needs of patients living with devastating diseases.
The climate crisis is a health crisis. That’s why we completed a life cycle assessment of three biosimilars products, creating a roadmap to reduce our environmental impact. It’s one way we’re working to go fossil fuel free.
Better access to healthcare equals better health outcomes. Learn about our Community Advisory Board and how 100% of the U.S. clinical trial studies we initiated in 2021 included a plan to recruit underrepresented patients.
Our promise is that employees will receive equal pay for equal work. We’re disclosing data like our global gender pay gap, which builds on our pay equity analysis.
Transparency across ESG issues is a key part of our collaboration with stakeholders. We are an early adopter of the new U.N. Global Compact reporting framework.